Find an Article

Filter articles

Applied Filters

Showing 141 to 150 of 274 results

SPCs: a state of conflict


Despite several major EU rulings on supplementary protection certificates, national IP offices and courts can form differing interpretations, and it seems that a unitary-style SPC right would be hard to create. LSIPR reports.

Patent analysis: CRISPR technology in India

India, US19-05-2016Hemant Singh

It is likely that many patent applications directed to CRISPR technology will be filed in India, says Hemant Singh of Inttl Advocare, who analyses some of the early applications and the rules on patentability.

Squatters’ rights: the problem with third party SPCs

EU12-05-2016Trevor Cook

There is a lack of judicial guidance in Europe on the issue of third party supplementary protection certificates (SPCs), otherwise known as “SPC squatting”, as Trevor Cook of WilmerHale explains.

What the future holds for second medical use patents

International28-04-2016Charlotte Weekes and Tamsin Cornwell

Ahead of the English Court of Appeal’s hearing in May in the Warner-Lambert case on second medical use patents, Charlotte Weekes and Tamsin Cornwell of Pinsent Masons examine some of the unanswered questions.

What Canada can learn from SPCs in Europe

Canada, EU21-04-2016Shirley Liang

Unlike in the EU, Canada does not have additional pharma patent protection to compensate for regulatory delays, but that looks set to change, as Shirley Liang, an IP lawyer in Canada, explains.

A sense of relief: enforcing second medical use patents

UK31-03-2016Katie Hutchinson

Owners of second medical use patents may need to think outside the box in terms of the relief they seek for infringement, says Katie Hutchinson of Bristows.

A second bite at the cherry

EU24-03-2016Joachim Wachenfeld and Oswin Ridderbusch

Despite a large body of EPO case law accepting second medical use claims that recite a novel technical effect, all eyes are on how courts in EPC member states will deal with infringement cases arising from such patents. Joachim Wachenfeld and Oswin Ridderbusch of Vossius & Partner report.

Avoiding the Actavis SPC trap

International09-03-2016David Carling and Michael Pears

The UK Intellectual Property Office has issued a favourable decision on an SPC for an “innovative” combination product. David Carling and Michael Pears of Potter Clarkson explain the reasoning and examine its implications.

Case report: Eli Lilly loses latest Alimta battle

UK08-03-2016David Read

In February the English High Court ruled that Actavis had not indirectly infringed a patent owned by Eli Lilly directed to cancer drug Alimta. David Read of Bartle Read reports.

Second medical use patents: why generics are in the dark

International03-03-2016Deborah Hart

Despite several UK court decisions centring on second medical use patents, there are no foolproof ways for generic manufacturers to avoid infringement, as Deborah Hart of Kilburn & Strode explains.

Showing 141 to 150 of 274 results